Opinion

Video

Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Current Time 0:00
Duration 3:36
Loaded: 0%
Stream Type LIVE
Remaining Time 3:36
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following questions:

    • In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
    • Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?
    Related Videos
    4 experts in this video
    Non–Muscle Invasive-Bladder Cancer Overview
    Laura Davis, MD, on link between microplastics and bladder cancer
    Laura Davis, MD, on link between microplastics and bladder cancer
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
    Expert discusses the NMIBC trials landscape
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
    Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Related Content
    Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
    May 15th 2025

    Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

    Tracey L. Krupski, MD Jeunice Owens-Walton, MD
    "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    May 9th 2025

    Durvalumab plus BCG significantly improves DFS in NMIBC

    Benjamin P. Saylor Hannah Clarke
    The data are to be presented at an upcoming medical conference.
    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
    December 7th 2021

    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

    Urology Times staff
    “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
    FDA to host advisory committee meeting on UGN-102 for NMIBC
    May 7th 2025

    FDA to host advisory committee meeting on UGN-102 for NMIBC

    Hannah Clarke
    The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
    May 5th 2025

    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

    Hannah Clarke
    The sBLA for NAI was submitted to the FDA in March 2025.
    © 2025 MJH Life Sciences

    All rights reserved.